Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients
21 Giugno 2023 - 2:19PM
Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading
the way in innovative diagnostic solutions, announced that the
China National Intellectual Property Administration (CNIPA) has
issued a Notice of Allowance for a patent application that covers a
development stage information technology (“IT”) system that
includes an artificial Intelligence (AI) claim aimed at assisting
individuals to protect themselves against potential adverse
reactions to specific food ingredients. Among other things, the
patent claims focus on systems, algorithms and methods to help
patients avoid potentially harmful food items based on their unique
medical data.
The patent encompasses a host of IT methods to evaluate,
predict, learn and update the potential health risks associated
with consuming specific prepared food items, based on a patient's
medical data. By deriving a confidence level from the patient's
health records including a patient’s elevated immune response to
specific food ingredients, including those identified through the
Biomerica inFoods® IBS test, or other foods that cause adverse
reactions such as gluten intolerance, an IT system could be
designed to assess the likelihood of an adverse reaction to a
common packaged or prepared food that may contain the food
ingredient the patient needs to avoid.
Leveraging two sets of data, the invention formulates a safety
level for each food item in each specific patient. Consequently, a
system could be designed to enable an application (App) on a phone,
iPad or computer to screen packaged or prepared foods to identify
if the packaged or prepared food contains an ingredient previously
identified as harmful to the patient. The technology could also
recommend alternative packaged or prepared foods that do not
contain the previously identified harmful food ingredient.
This patented approach could bridge the gap between healthcare
and diet, designed to allow individuals with a variety of medical
conditions, allergies, illnesses and food intolerances, whose
symptoms are caused or exasperated by consumption of specific food
ingredients, to have more control and confidence in their dietary
choices. The technology described in this patent that has been
issued the notice of allowance can contribute significantly to the
digital health sector, ushering in a new era of personalized and
preventive healthcare through the power of technology.
This patent further strengthens the Company’s robust
intellectual property portfolio in the area of science, diet and
technology. This is the second patent on this technology the
company has received, the first was issued in Japan.
"This notice of patent allowance is a step towards a safer, more
informed environment where individuals can confidently navigate
their dietary choices.” said Zack Irani the CEO of Biomerica. "This
recognition from the Chinese Patent Office of the novel and
inventive nature of this technology marks a significant step
forward in our longer-term ambition of facilitating happier
healthier lives globally."
The allowed patent application number in China is 201680054790.9
and can be viewed at:
https://biomerica.com/inFoods/our-technology/
About inFoods IBS:
Unlike traditional IBS treatments that rely on medications to
mask symptoms, inFoods® IBS is a personalized and natural treatment
approach. The inFoods IBS test is based on a patented technology
that identifies the specific foods that can trigger IBS symptoms in
individual patients. Once the trigger food(s) have been identified,
patients who remove these trigger foods from their diets often
experience a significant reduction or elimination in their IBS
symptoms. A double blinded placebo controlled clinical study
(performed at Mayo Clinic, Beth Israel Deaconess Medical Center
Inc., a Harvard Medical School Teaching Hospital, the University of
Michigan, Houston Methodist Hospital, and others), showed the
inFoods® IBS treatment diet significantly improved several key IBS
symptoms including Abdominal Pain Intensity (API). Symptom
improvement in API for patients in the treatment arm versus the
placebo arm was similar to, and in some cases better than, the
improvement seen from current IBS drugs in the market, but without
the drug side effects. Further information about Biomerica’s
patented inFoods® Products and Technology Platform can be found at:
https://biomerica.com/infoods/
About Biomerica (NASDAQ:
BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point of
care (in home and in physicians’ offices) and in hospital/clinical
laboratories for detection and/or treatment of medical conditions
and diseases. The Company’s products are designed to enhance the
health and well-being of people, while reducing total healthcare
costs. Biomerica’s primary focus is on gastrointestinal and
inflammatory diseases where the Company has multiple diagnostic and
therapeutic products in development.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to: the possibly future development of an
information technology system that utilizes artificial intelligence
to guide a patient’s dietary choices, and the market opportunities
from such a system; the Company’s intellectual property; inFoods®
IBS test and other tests; allowance and or clearance of patent
applications in China and in other countries; FDA or other
regulatory clearance or possible future clearance of products that
can be developed and commercialized, utilizing the technology
described in the Company’s patent applications; the novel nature of
the patented technology and the freedom to operate within the field
of use described in patent applications; the development of systems
incorporating the patented technology; and the assessment
capabilities of a system to detect potential adverse reactions.
Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results
in the future, including, without limitation: results of studies
testing the efficacy of products incorporating the patented
technology; regulatory approvals necessary prior to
commercialization any of the Company’s products; commercial
acceptance of products incorporating the patented technology;
governmental import/export regulations; demand for our various
tests and other products; competition from other similar products
and from competitors that have significantly more financial and
other resources available to them and such other risks disclosed in
the our reports (such as Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K) filed with
the SEC and available on the SEC's Internet site
(http://www.sec.gov). Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. The Company is under no
obligation to update any forward-looking statements after the date
of this release.
Corporate Contact:
Zack Irani-Cohen
949-645-2111
investors@biomerica.com
Source: Biomerica, Inc.
Grafico Azioni Biomerica (NASDAQ:BMRA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Biomerica (NASDAQ:BMRA)
Storico
Da Set 2023 a Set 2024